Table 1 FDA approved cancer drugs from 2010 to 2020
From: Phyto-factories of anti-cancer compounds: a tissue culture perspective
Drug name | Treatment | Approval status | Company name |
|---|---|---|---|
Halaven (eribulin mesylate) | Breast cancer | Nov 2010 | Eisai |
Herceptin (trastuzumab) | Gastric cancer | Oct 2010 | Genentech |
Jevtana (cabazitaxel) | Prostate cancer | Jun 2010 | Sanofi aventis |
Abstral (fentanyl sublingual tablets) | Cancer pain in opioid-tolerant patients | Jan 2011 | ProStrakan |
Lazanda (fentanyl citrate) nasal spray | Cancer pain | Jun 2011 | Archimedes |
Vandetanib (vandetanib) | Thyroid cancer | Apr 2011 | AstraZeneca |
Xalkori (crizotinib) | ALK + non-small cell lung cancer | Aug 2011 | Pfizer |
Zytiga (abiraterone acetate) | Prostate cancer | May 2011 | Centocor Ortho Biotech |
Cometriq (cabozantinib) | Metastatic medullary thyroid cancer | Nov 2012 | Exelixis |
Abraxane (paclitaxel protein-bound particles for injectable suspension) | Non-small cell lung cancer, | Oct 2012 | Celgene |
Perjeta (pertuzumab) | First-line treatment of HER2 + metastatic breast cancer | June 2012 | Genentech |
Afinitor (everolimus) | HER2-negative breast cancer | July 2012 | Novartis |
Cometriq (cabozantinib) | Metastatic medullary thyroid cancer | Nov 2012 | Exelixis |
Stivarga (regorafenib) | For the treatment of previously treated patients with metastatic colorectal cancer | Sept 2012 | Bayer HealthCare Pharmaceuticals |
Subsys (fentanyl sublingual spray) | Treatment of breakthrough cancer pain | Jan 2012 | Insys Therapeutics |
Xtandi (enzalutamide) | Metastatic castration-resistant prostate cancer | Aug 2012 | Medivation |
Zaltrap (ziv-aflibercept) | Treatment of metastatic colorectal cancer | Aug 2012 | Sanofi-aventis |
Gilotrif (afatinib) | Metastatic non-small cell lung cancer with EGFR mutations, Approved July 2013 | July 2013 | Boehringer Ingelheim |
Kadcyla (ado-trastuzumab emtansine) | Treatment of HER2-positive metastatic breast cancer | Feb 2013 | Genentech |
Xofigo (radium Ra 223 dichloride) | Treatment of prostate cancer with bone metastases | May 2013 | Bayer Healthcare Pharmaceuticals |
Cyramza (ramucirumab) | Treatment of gastric cancer | April 2014 | Eli Lilly |
Avastin (bevacizumab) | Treatment of persistent, recurrent, or metastatic cervical cancer | Aug 2014 | Genentech |
Avastin (bevacizumab) | Treatment of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer | Nov 2014 | Genentech |
Lynparza (olaparib) | Treatment of previously treated BRCA mutated advanced ovarian cancer | Dec 2014 | AstraZeneca |
Zykadia (ceritinib) | Treatment of ALK + metastatic non-small cell lung cancer | April 2014 | Novartis |
Lonsurf (trifluridine and tipiracil) | Treatment of metastatic colorectal cancer | Sept 2015 | Taiho Oncology |
Onivyde (irinotecan liposome injection) | Treatment of metastatic pancreatic cancer following gemcitabine-based therapy | Oct 2015 | Merrimack |
Ibrance (palbociclib) | Treatment of HR-positive, HER2-negative breast cancer, | Feb 2015 | Pfizer |
Alecensa (alectinib) | Treatment of ALK-positive, metastatic non-small cell lung cancer | Dec 2015 | Roche |
Keytruda (pembrolizumab) | Treatment of PD-L1 positive advanced non-small cell lung cancer | Oct 2015 | Merck |
Lonsurf (trifluridine and tipiracil) | Treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma | Sept 2015 | Taiho Oncology |
Onivyde (irinotecan liposome injection) | Treatment of metastatic pancreatic cancer following gemcitabine-based therapy | Oct 2015 | Merrimack |
Opdivo (nivolumab) | Treatment of metastatic squamous non-small cell lung cancer | March 2015 | Bristol–Myers Squibb |
Portrazza (necitumumab) | Treatment of metastatic squamous non-small cell lung cancer | Nov 2015 | Eli Lilly |
Tagrisso (osimertinib) | Treatment of EGFR T790M mutation positive non-small cell lung cancer | Nov 2015 | AstraZeneca |
Alecensa (alectinib) | Treatment of ALK-positive, metastatic non-small cell lung cancer | Dec 2015 | Roche |
Keytruda (pembrolizumab) | Treatment of PD-L1 positive advanced non-small cell lung cancer | Oct 2015 | Merck |
Opdivo (nivolumab) | Treatment of metastatic squamous non-small cell lung cancer | March 2015 | Bristol–Myers Squibb |
Portrazza (necitumumab) | Treatment of metastatic squamous non-small cell lung cancer | Nov 2015 | Eli Lilly |
Tagrisso (osimertinib) | Treatment of EGFR T790M mutation positive non-small cell lung cancer | Nov 2015 | AstraZeneca |
Syndros (dronabinol oral solution) | Tomiting associated with cancer chemotherapy | July 2016 | Insys Therapeutics |
Rubraca (rucaparib) | Treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation | Dec 2016 | Clovis Oncology |
Keytruda (pembrolizumab) | Treatment of head and neck squamous cell cancer | Aug 2016 | Merck |
Tecentriq (atezolizumab) | Treatment of urothelial carcinoma and metastatic non-small cell lung cancer | May 2016 | Genentech |
Keytruda (pembrolizumab) | Treatment of microsatellite instability-high or mismatch repair deficient solid tumors and colorectal cancer | May 2017 | Merck |
Kisqali (ribociclib) | Treatment of breast cancer | March 2017 | Novartis |
Verzenio (abemaciclib) | Treatment of HR + , HER2-breast cancer | Sept 2017 | Eli Lilly |
Zejula (niraparib) | Treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer | March 2017 | Tesaro |
Alunbrig (brigatinib) | Treatment of advanced ALK-positive metastatic non-small cell lung cancer | April 2017 | Ariad Pharmaceuticals |
Imfinzi (durvalumab) | Treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer | May 2017 | AstraZeneca |
Keytruda (pembrolizumab) | Treatment of urothelial carcinoma (bladder cancer) | May 2017 | Merck |
Nerlynx (neratinib) | Treatment of HER2 breast cancer | July 2017 | Puma Biotech |
Keytruda (pembrolizumab) | Treatment of recurrent or metastatic cervical cancer | June 2018 | Merck |
Talzenna (talazoparib) | Treatment of deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer | Oct 2018 | Pfizer |
Erleada (apalutamide) | Treatment of prostate cancer | Feb 2018 | Janssen Oncology |
Keytruda (pembrolizumab) | Treatment of recurrent or metastatic cervical cancer | June 2018 | Merck |
Lorbrena (lorlatinib) | Treatment of ALK-positive metastatic non-small cell lung cancer | Nov 2018 | Pfizer |
Opdivo (nivolumab) | Treatment of advanced small cell lung cancer | Aug 2018 | Bristol–Myers Squibb |
Opdivo (nivolumab) | Treatment of MSI-H or dMMR metastatic colorectal cancer | Aug 2018 | Bristol–Myers Squibb |
Talzenna (talazoparib) | Treatment of deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer | Oct 2018 | Pfizer |
Vizimpro (dacomitinib) | Treatment of metastatic non-small cell lung cancer | Sept 2018 | Pfizer |
Erleada (apalutamide) | Treatment of prostate cancer, | Feb 2018 | Janssen Oncology |
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) | Treatment of HER2-overexpressing breast cancer, | Feb 2019 | Halozyme |
Piqray (alpelisib) | Treatment of HR + , HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer | May 2019 | Novartis |
Tecentriq (atezolizumab) | Treatment of triple negative breast cancer | March 2019 | Genentech/Roche |
Keytruda (pembrolizumab) | Treatment of stage III non-small cell lung cancer, | April 2019 | Merck |
Tecentriq (atezolizumab) | Treatment of extensive-stage small cell lung cancer | March 2019 | Genentech/Roche |
Balversa (erdafitinib) | Treat adult patients with locally advanced or metastatic bladder cancer | April 2019 | Janssen Products, LP |
Piqray (alpelisib) | Treatment of breast cancer | May 2019 | Novartis |
Polivy (polatuzumab vedotin-piiq) | Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma | June 2019 | Genentech |
Brigatinib | Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) | May 2020 | ARIAD Pharmaceuticals Inc |
Olaparib | First-line treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer | May 2020 | AstraZeneca |
Pembrolizumab | Hodgkin lymphoma (Chl) | Oct 2020 | Merck Sharp & Dohme Corp |
Nivolumab + ipilimumab | Treatment for unresectable malignant pleural mesothelioma | Oct 2020 | Bristol-Myers Squibb Co |